| |
Fig. 7. miR-96 MO phenotype. A. Loss of miR-96 function was accompanied by eye malformations (white arrows). B. Injection of 20 ng miR-96 MO resulted in a slight downregulation of Rx1 and Pax6 on the injected side at stage 13 (black arrows). C. At stage 23, depletion of miR-96 led to a strong downregulation of Rx1 and Pax6 on the injected side (black arrows). Emx1 and Krox20 were not affected, whereas the expression domain of En2 was broadened in around 27% of the analyzed embryos (black arrow). D. The downregulation of miR-96 was followed by a reduction of the cranial cartilage on the MO-injected side of the embryo (black arrows). The cartilage preparation of the control MO injected embryo is identical to Fig. 6D. E. At stage 17, the expression of Slug and FoxD3 was disturbed after loss of miR-96 function (black arrows). E. At stage 20, FoxD3 expression was downregulated on the injected side. At stage 23, Krox20 and Twist were reduced after the injection of 20 ng miR-96 MO (black arrows). For all shown experiments, quantitative representations are given. n = number of independent experiments; N = number of analyzed embryos. |
